

# Cancer Gene Therapy Market Size, Share & Trends Analysis Report By Therapy (Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer), By End-use, By Region, And Segment Forecasts, 2022 -2030

https://marketpublishers.com/r/CFAFE1E8F6B5EN.html

Date: October 2022

Pages: 150

Price: US\$ 5,950.00 (Single User License)

ID: CFAFE1E8F6B5EN

## **Abstracts**

This report can be delivered to the clients within 3 Business Days

Cancer Gene Therapy Market Growth & Trends

The global cancer gene therapy market size is expected to reach USD 8.7 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to register a CAGR of 19.99% from 2022 to 2030 owing to the increasing demand for novel therapeutics globally and rising incidence of cancer cases globally. Moreover, this therapy offers an absolute solution to different kinds of inherited and induced cancer conditions, which makes it a more desired option for cancer therapeutics. For instance, Kite's Tecartus (brexucabtagene autoleucel) is approved by the FDA for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

There is an increasing prevalence of malignant tumor cases across the globe, which is expected to propel the need for various strategies for effective treatment and to combat the increasing incidence of malignant tumors. Moreover, technological advancements in the market are expected to provide new opportunities for novel therapeutics. As a result, there is an increasing number of product approvals. For instance, in March 2022, European Medicine Agency recommended conditional marketing authorization for Carvykti (ciltacabtagene autoleucel) to be used for the treatment of subjects with relapsed and refractory multiple myeloma.



The market is positively driven by the lucrative support from the government and national cancer societies across the globe. There has been an increasing focus on increasing funds for research on cancer gene therapy. For instance, in December 2021, The Dutch platform called DARE-NL (in the Netherlands) has been awarded a USD 5.2 million grant from the KWF Dutch cancer society. The grant allows the DARE-NL to level up the availability of cell and gene therapy strategies accessible to the needy population.

The investment in new and complex technologies is relatively low for Asian manufacturers as they are more focused on less complex molecules that can be produced in bulk. Thus, the investment in high-yielding, low-cost technologies is an alternative for manufacturers in other developed regions such as Europe and North America to avoid competitive pressure.

Key players operating in the market are focusing on collaborations for the development of potent cancer gene therapy drugs. For instance, in August 2022, Gensaic signed a collaboration with Ovid Therapeutics for the development of up to three genetic medicines for central nervous system indications using its proprietary phage-derived particle gene therapy platform.

Cancer Gene Therapy Market Report Highlights

The market is witnessing a key shift with the rise in gene level understanding of a cancer condition and rising need for gene induced immunotherapy and personalized medicine

The gene induced immunotherapy segment held the largest share in 2021 due to increase in the advancement in gene induced immunotherapy research

Biopharmaceutical companies held the largest market share in 2021 owing to rising demand for novel gene therapy and increasing number of FDA approvals for cancer gene therapy. Biopharmaceutical companies are anticipated to witness the fastest growth in the forecast period due to increasing research and development activities in the field

North America dominated the market in 2021 due to the presence of key players and rising support from the government and National Cancer Institute to advance the research on oncology in the region



### **Contents**

### CHAPTER 1 CANCER GENE THERAPY MARKET: METHODOLOGY AND SCOPE

- 1.1 Market Segmentation
  - 1.1.1 Segment Scope
  - 1.1.2 Regional Scope
  - 1.1.3 Estimates And Forecast Timeline
- 1.2 Research Methodology
- 1.3 Information Procurement
  - 1.3.1 Purchased Database
  - 1.3.2 Gvr's Internal Database
  - 1.3.3 Secondary Sources
- 1.3.4 Primary Research
- 1.3.5 Details of Primary Research
- 1.4 Information Or Data Analysis
  - 1.4.1 Data Analysis Models
- 1.5 Market Formulation & Validation
- 1.6 Model Details
  - 1.6.1 Commodity Flow Analysis
    - 1.6.1.1 Approach 1: Commodity Flow Approach
    - 1.6.1.2 Approach 2: Country Wise Market Estimation Using Bottom Up Approach
    - 1.6.1.3 Approach 2: Country Wise Market Estimation Using Top Down Approach
- 1.7 Global Market: CAGR Calculation
- 1.8 Regional Market: CAGR Calculation
- 1.9 List of Secondary Sources
- 1.10 Objectives
  - 1.10.1 Objective 1:
  - 1.10.2 Objective 2:
- 1.11 List of Abbreviations

### CHAPTER 2 CANCER GENE THERAPY MARKET: EXECUTIVE SUMMARY

- 2.1 Cancer Gene Therapy Market: Market Outlook
  - 2.1.1 Market Summary

### CHAPTER 3 CANCER GENE THERAPY MARKET: INDUSTRY OUTLOOK

3.1 Market Lineage Outlook



- 3.1.1 Parent Market Lineage Outlook
- 3.1.2 Related/Ancillary Market Outlook
- 3.2 Penetration & Growth Prospect Mapping
- 3.3 Market Dynamics
  - 3.3.1 Market Drivers
  - 3.3.1.1 High growth of the pharmaceutical industry
  - 3.3.1.2 Rising R&D investements and demand for novel cancer therapeutics
  - 3.3.1.3 Increased incidence of cancers
  - 3.3.1.4 Technological advancements
  - 3.3.2 Market Restraint Analysis
  - 3.3.2.1 High product prices
  - 3.3.2.2 Unethical use of gene therapy
- 3.4 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
- 3.5 Industry Analysis Porter's
- 3.6 Reimbursement & Regulatory Scenario
- 3.7 Major Deals & Strategic Alliances
  - 3.7.1 New Product Launch
  - 3.7.2 Acquisition
  - 3.7.3 Expansion
  - 3.7.4 Partnerships
  - 3.7.5 Marketing & Promotions

### CHAPTER 4 CANCER GENE THERAPY MARKET: COMPETITIVE LANDSCAPE

- 4.1 Recent Developments & Impact Analysis, By Key Market Participants
  - 4.1.1 Ansoff Matrix
- 4.2 Company Categorization
  - 4.2.1 Innovators
    - 4.2.1.1 Market Differentiators
- 4.3 Vendor Landscape
  - 4.3.1 List Of Key Distributors And Channel Partners
  - 4.3.2 Key Customers
  - 4.3.3 Key Company Market Share Analysis, 2021
- 4.4 Public Companies
  - 4.4.1 Competitive Dashboard Analysis
- 4.5 Private Companies
  - 4.5.1 List Of Key Emerging Companies
- 4.6 Regional Network Map



### **CHAPTER 5 CANCER GENE THERAPY MARKET: THERAPY ANALYSIS**

- 5.1 Cancer Gene Therapy Market: Therapy Movement Analysis
- 5.2 Oncolytic Virotherapy
- 5.2.1 Oncolytic virotherapy market estimates and forecast, 2018 2030 (USD Million)
- 5.3 Gene Induced Immunotherapy
- 5.3.1 Gene induced immunotherapy market estimates and forecast, 2018 2030 (USD Million)
- 5.4 Gene Transfer
  - 5.3.1 Gene transfer market estimates and forecast, 2018 2030 (USD Million)

#### CHAPTER 6 CANCER GENE THERAPY MARKET: END-USE ANALYSIS

- 6.1 Cancer Gene Therapy Market: End-Use Movement Analysis
- 6.2 Research Institutes
- 6.2.1 Research institutes based cancer gene therapy market estimates and forecast,
- 2018 2030 (USD Million)
- 6.3 Biopharmaceutical Companies
- 6.3.1 Biopharmaceutical companies based cancer gene therapy market estimates and forecast, 2018 2030 (USD Million)
- 6.4 Diagnostic Centres
- 6.4.1 Diagnostic centres based cancer gene therapy market estimates and forecast,
- 2018 2030 (USD Million)
- 6.5 Other End-use
- 6.5.1 Other end-use based cancer gene therapy market estimates and forecast, 2018 2030 (USD Million)

# CHAPTER 7 CANCER GENE THERAPY MARKET: REGIONAL BUSINESS ANALYSIS

- 7.1 Market Share Analysis by Country, 2021 & 2030
  - 7.1.1 North America
    - 7.1.1.1 North America market estimates and forecast, 2018 2030 (USD Million)
    - 7.1.1.2 U.S.
    - 7.1.1.2.1 U.S. market estimates and forecast, 2018 2030 (USD Million)
    - 7.1.1.3 Canada
      - 7.1.1.3.1 Canada market estimates and forecast, 2018 2030 (USD Million)
  - **7.1.2** Europe
    - 7.1.2.1 Europe market estimates and forecast, 2018 2030 (USD Million)



- 7.1.2.2 U.K.
  - 7.1.2.2.1 U.K. market estimates and forecast, 2018 2030 (USD Million)
- 7.1.2.3 Germany
- 7.1.2.3.1 Germany market estimates and forecast, 2018 2030 (USD Million)
- 7.1.2.4 France
- 7.1.2.4.1 France market estimates and forecast, 2018 2030 (USD Million)
- 7.1.2.5 Italy
- 7.1.2.5.1 Italy market estimates and forecast, 2018 2030 (USD Million)
- 7.1.2.6 Spain
- 7.1.2.6.1 Spain market estimates and forecast, 2018 2030 (USD Million)
- 7.1.3 Asia Pacific
  - 7.1.3.1 Asia Pacific market estimates and forecast, 2018 2030 (USD Million)
  - 7.1.3.2 Japan
  - 7.1.3.2.1 Japan market estimates and forecast, 2018 2030 (USD Million)
  - 7.1.3.3 China
  - 7.1.3.3.1 China market estimates and forecast, 2018 2030 (USD Million)
  - 7.1.3.4 India
  - 7.1.3.4.1 India market estimates and forecast, 2018 2030 (USD Million)
  - 7.1.3.5 South Korea
    - 7.1.3.5.1 South Korea market estimates and forecast, 2018 2030 (USD Million)
  - 7.1.3.6 Australia
  - 7.1.3.6.1 Australia market estimates and forecast, 2018 2030 (USD Million)
- 7.1.4 Latin America
  - 7.1.4.1 Latin America market estimates and forecast, 2018 2030 (USD Million)
  - 7.1.4.2 Brazil
  - 7.1.4.2.1 Brazil market estimates and forecast, 2018 2030 (USD Million)
  - 7.1.4.3 Mexico
    - 7.1.4.3.1 Mexico market estimates and forecast, 2018 2030 (USD Million)
  - 7.1.4.4 Argentina
  - 7.1.4.4.1 Argentina market estimates and forecast, 2018 2030 (USD Million)
- 7.1.5 Middle East And Africa
- 7.1.5.1 Middle East & Africa market estimates and forecast, 2018 2030 (USD Million)
  - 7.1.5.2 South Africa
  - 7.1.5.2.1 South Africa market estimates and forecast, 2018 2030 (USD Million)
  - 7.1.5.3 Saudi Arabia
    - 7.1.5.3.1 Saudi Arabia market estimates and forecast, 2018 2030 (USD Million)
  - 7.1.5.4 UAE
    - 7.1.5.4.1 UAE market estimates and forecast, 2018 2030 (USD Million)



### CHAPTER 8 CANCER GENE THERAPY MARKET: COMPANY PROFILING

- 8.1 Company Profiles
  - 8.1.1 Abeona Therapeutics Inc.
    - 8.1.1.1 Company overview
    - 8.1.1.2 Financial performance
    - 8.1.1.3 Product benchmarking
    - 8.1.1.4 Strategic initiatives
  - 8.1.2 Asklepios BioPharmaceutical Inc.
    - 8.1.2.1 Company overview
    - 8.1.2.2 Financial performance
    - 8.1.2.3 Product benchmarking
    - 8.1.2.4 Strategic initiatives
  - 8.1.3 Celgene(Bristol-Myers Squibb Company)
    - 8.1.3.1 Company overview
    - 8.1.3.2 Financial performance
    - 8.1.3.3 Product benchmarking
  - 8.1.3.4 Strategic initiatives
  - 8.1.4 Elevate Bio
    - 8.1.4.1 Company overview
    - 8.1.4.2 Financial performance
    - 8.1.4.3 Product benchmarking
    - 8.1.4.4 Strategic initiatives
  - 8.1.5 GlaxoSmithKline Inc.
    - 8.1.5.1 Company overview
    - 8.1.5.2 Financial performance
    - 8.1.5.3 Product benchmarking
    - 8.1.5.4 Strategic initiatives
  - 8.1.6 Bluebird bio Inc.
    - 8.1.6.1 Company overview
    - 8.1.6.2 Financial performance
    - 8.1.6.3 Product benchmarking
    - 8.1.6.4 Strategic initiatives
  - 8.1.7 Genelux Corporation
    - 8.1.7.1 Company overview
    - 8.1.7.2 Financial performance
    - 8.1.7.3 Product benchmarking
    - 8.1.7.4 Strategic initiatives



- 8.1.8 OncoGenex Pharmaceuticals Inc.
  - 8.1.8.1 Company overview
  - 8.1.8.2 Financial performance
  - 8.1.8.3 Product benchmarking
  - 8.1.8.4 Strategic initiatives
- 8.1.9 Introgen Therapeutics Inc.
- 8.1.9.1 Company overview
- 8.1.9.2 Financial performance
- 8.1.9.3 Product benchmarking
- 8.1.9.4 Strategic initiatives
- 8.1.10 Altor Bioscience Inc.
  - 8.1.10.1 Company overview
  - 8.1.10.2 Financial performance
  - 8.1.10.3 Product benchmarking
  - 8.1.10.4 Strategic initiatives
- 8.1.11 Merck & Co., Inc.
  - 8.1.11.1 Company overview
  - 8.1.11.2 Financial performance
  - 8.1.11.3 Product benchmarking
  - 8.1.11.4 Strategic initiatives
- 8.1.12 GenVec
  - 8.1.12.1 Company overview
  - 8.1.12.2 Financial performance
  - 8.1.12.3 Product benchmarking
  - 8.1.12.4 Strategic initiatives
- 8.1.13 BioCancell Inc.
  - 8.1.13.1 Company overview
  - 8.1.13.2 Financial performance
  - 8.1.13.3 Product benchmarking
  - 8.1.13.4 Strategic initiatives
- 8.2 List of Other Key Players



# **List Of Tables**

### LIST OF TABLES

- TABLE 1 List of Secondary Sources
- TABLE 2 List of Abbreviations
- TABLE 3 Incidence of Diseases
- TABLE 4 Global Cancer Gene Therapy Market, By Region, 2018 2030 (USD Million)
- TABLE 5 Global Cancer Gene Therapy Market, By Therapy, 2018 2030 (USD Million)
- TABLE 6 Global Cancer Gene Therapy Market, By End-use, 2018 2030 (USD Million)
- TABLE 7 North America Cancer Gene Therapy Market, By Country, 2018 2030 (USD Million)
- TABLE 8 North America Cancer Gene Therapy Market, By Therapy, 2018 2030 (USD Million)
- TABLE 9 North America Cancer Gene Therapy Market, By End-use, 2018 2030 (USD Million)
- TABLE 10 U.S. Cancer Gene Therapy Market, By Therapy, 2018 2030 (USD Million)
- TABLE 11 U.S. Cancer Gene Therapy Market, By End-use, 2018 2030 (USD Million)
- TABLE 12 Canada Cancer Gene Therapy Market, By Therapy, 2018 2030 (USD Million)
- TABLE 13 Canada Cancer Gene Therapy Market, By End-use, 2018 2030 (USD Million)
- TABLE 14 Europe Cancer Gene Therapy Market, By Country, 2018 2030 (USD Million)
- TABLE 15 Europe Cancer Gene Therapy Market, By Therapy, 2018 2030 (USD Million)
- TABLE 16 Europe Cancer Gene Therapy Market, By End-use, 2018 2030 (USD Million)
- TABLE 17 Germany Cancer Gene Therapy Market, By Therapy, 2018 2030 (USD Million)
- TABLE 18 Germany Cancer Gene Therapy Market, By End-use, 2018 2030 (USD Million)
- TABLE 19 U.K. Cancer Gene Therapy Market, By Therapy, 2018 2030 (USD Million)
- TABLE 20 U.K. Cancer Gene Therapy Market, By End-use, 2018 2030 (USD Million)
- TABLE 21 France Cancer Gene Therapy Market, By Therapy, 2018 2030 (USD Million)
- TABLE 22 France Cancer Gene Therapy Market, By End-use, 2018 2030 (USD Million)
- TABLE 23 Italy Cancer Gene Therapy Market, By Therapy, 2018 2030 (USD Million)



- TABLE 24 Italy Cancer Gene Therapy Market, By End-use, 2018 2030 (USD Million)
- TABLE 25 Spain Cancer Gene Therapy Market, By Therapy, 2018 2030 (USD Million)
- TABLE 26 Spain Cancer Gene Therapy Market, By End-use, 2018 2030 (USD Million)
- TABLE 27 Asia Pacific Cancer Gene Therapy Market, By Country, 2018 2030 (USD Million)
- TABLE 28 Asia Pacific Cancer Gene Therapy Market, By Therapy, 2018 2030 (USD Million)
- TABLE 29 Asia pacific Cancer Gene Therapy Market, By End-use, 2018 2030 (USD Million)
- TABLE 30 Japan Cancer Gene Therapy Market, By Therapy, 2018 2030 (USD Million)
- TABLE 31 Japan Cancer Gene Therapy Market, By End-use, 2018 2030 (USD Million)
- TABLE 32 China Cancer Gene Therapy Market, By Therapy, 2018 2030 (USD Million)
- TABLE 33 China Cancer Gene Therapy Market, By End-use, 2018 2030 (USD Million)
- TABLE 34 India Cancer Gene Therapy Market, By Therapy, 2018 2030 (USD Million)
- TABLE 35 India Cancer Gene Therapy Market, By End-use, 2018 2030 (USD Million)
- TABLE 36 South Korea Cancer Gene Therapy Market, By Therapy, 2018 2030 (USD Million)
- TABLE 37 South Korea Cancer Gene Therapy Market, By End-use, 2018 2030 (USD Million)
- TABLE 38 Australia Cancer Gene Therapy Market, By Therapy, 2018 2030 (USD Million)
- TABLE 39 Australia Cancer Gene Therapy Market, By End-use, 2018 2030 (USD Million)
- TABLE 40 Latin America Cancer Gene Therapy Market, By Country, 2018 2030 (USD Million)
- TABLE 41 Latin America Cancer Gene Therapy Market, By Therapy, 2018 2030 (USD Million)
- TABLE 42 Latin America Cancer Gene Therapy Market, By End-use, 2018 2030 (USD Million)
- TABLE 43 Brazil Cancer Gene Therapy Market, By Therapy, 2018 2030 (USD Million)
- TABLE 44 Brazil Cancer Gene Therapy Market, By End-use, 2018 2030 (USD Million)
- TABLE 45 Mexico Cancer Gene Therapy Market, By Therapy, 2018 2030 (USD Million)
- TABLE 46 Mexico Cancer Gene Therapy Market, By End-use, 2018 2030 (USD Million)
- TABLE 47 Argentina Cancer Gene Therapy Market, By Therapy, 2018 2030 (USD Million)
- TABLE 48 Argentina Cancer Gene Therapy Market, By End-use, 2018 2030 (USD Million)



TABLE 49 Middle East & Africa Cancer Gene Therapy Market, By Country, 2018 - 2030 (USD Million)

TABLE 50 Middle East & Africa Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)

TABLE 51 Middle East & Africa Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)

TABLE 52 Saudi Arabia Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)

TABLE 53 Saudi Arabia Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)

TABLE 54 South Africa Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)

TABLE 55 South Africa Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)

TABLE 56 UAE Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million) TABLE 57 UAE Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)



# **List Of Figures**

### LIST OF FIGURES

- FIG. 1 Information Procurement
- FIG. 2 Primary Research Pattern
- FIG. 3 Market Research Approaches
- FIG. 4 Value Chain-Based Sizing & Forecasting
- FIG. 5 Market Formulation & Validation
- FIG. 6 Cancer Gene Therapy, Market Segmentation
- FIG. 7 Market Driver Relevance Analysis (Current & Future Impact)
- FIG. 8 Market Restraint Relevance Analysis (Current & Future Impact)
- FIG. 9 Market Challenge Relevance Analysis (Current & Future Impact)
- FIG. 10 Penetration & Growth Prospect Mapping
- FIG. 11 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
- FIG. 12 Porter's Five Forces Analysis
- FIG. 13 Market Penetration Vs Growth Prospect Mapping, 2021
- FIG. 14 Regional Marketplace: Key Takeaways
- FIG. 15 Global Cancer Gene Therapy Market, for Therapy, 2018 2030 (USD Million)
- FIG. 16 Global Cancer Gene Therapy Market, for Oncolytic Virotherapy, 2018 2030 (USD Million)
- FIG. 17 Global Cancer Gene Therapy Market, for Gene Induced Immunotherapy, 2018 2030 (USD Million)
- FIG. 18 Global Cancer Gene Therapy Market, for Gene Transfer, 2018 2030 (USD Million)
- FIG. 19 Global Cancer Gene Therapy Market, for End-Use, 2018 2030 (USD Million)
- FIG. 20 Global Cancer Gene Therapy Market, for Research Institutes, 2018 2030 (USD Million)
- FIG. 21 Global Cancer Gene Therapy Market, for BiopharmaceuticalCompanies, 2018 2030 (USD Million)
- FIG. 22 Global Cancer Gene Therapy Market, for Diagnostic Centers, 2018 2030 (USD Million)
- FIG. 23 Regional Outlook, 2021 & 2030
- FIG. 24 North America Cancer Gene Therapy Market, 2018 2030 (USD Million)
- FIG. 25 U.S. Cancer Gene Therapy Market, 2018 2030 (USD Million)
- FIG. 26 Canada Cancer Gene Therapy Market, 2018 2030 (USD Million)
- FIG. 27 Europe Cancer Gene Therapy Market, 2018 2030 (USD Million)
- FIG. 28 Germany Cancer Gene Therapy Market, 2018 2030 (USD Million)
- FIG. 29 U.K. Cancer Gene Therapy Market, 2018 2030 (USD Million)



- FIG. 30 France Cancer Gene Therapy Market, 2018 2030 (USD Million)
- FIG. 31 Italy Cancer Gene Therapy Market, 2018 2030 (USD Million)
- FIG. 32 Spain Cancer Gene Therapy Market, 2018 2030 (USD Million)
- FIG. 33 Asia Pacific Cancer Gene Therapy Market, 2018 2030 (USD Million)
- FIG. 34 Japan Cancer Gene Therapy Market, 2018 2030 (USD Million)
- FIG. 35 China Cancer Gene Therapy Market, 2018 2030 (USD Million)
- FIG. 36 India Cancer Gene Therapy Market, 2018 2030 (USD Million)
- FIG. 37 Australia Cancer Gene Therapy Market, 2018 2030 (USD Million)
- FIG. 38 South Korea Cancer Gene Therapy Market, 2018 2030 (USD Million)
- FIG. 39 Latin America Cancer Gene Therapy Market, 2018 2030 (USD Million)
- FIG. 40 Brazil Cancer Gene Therapy Market, 2018 2030 (USD Million)
- FIG. 41 Mexico Cancer Gene Therapy Market, 2018 2030 (USD Million)
- FIG. 42 Argentina Cancer Gene Therapy Market, 2018 2030 (USD Million)
- FIG. 43 Middle East and Africa Cancer Gene Therapy Market, 2018 2030 (USD Million)
- FIG. 44 South Africa Cancer Gene Therapy Market, 2018 2030 (USD Million)
- FIG. 45 Saudi Arabia Cancer Gene Therapy Market, 2018 2030 (USD Million)
- FIG. 46 UAE Cancer Gene Therapy Market, 2018 2030 (USD Million)



### I would like to order

Product name: Cancer Gene Therapy Market Size, Share & Trends Analysis Report By Therapy

(Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer), By End-use, By

Region, And Segment Forecasts, 2022 - 2030

Product link: <a href="https://marketpublishers.com/r/CFAFE1E8F6B5EN.html">https://marketpublishers.com/r/CFAFE1E8F6B5EN.html</a>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

# **Payment**

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <a href="https://marketpublishers.com/r/CFAFE1E8F6B5EN.html">https://marketpublishers.com/r/CFAFE1E8F6B5EN.html</a>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <a href="https://marketpublishers.com/docs/terms.html">https://marketpublishers.com/docs/terms.html</a>

To place an order via fax simply print this form, fill in the information below



and fax the completed form to +44 20 7900 3970